| Barchart Demo Center |
$7.71
+0.05 (+0.65%)
as of May 31, 2024
as of May 31, 2024
| Last | 7.71 |
|---|---|
| Change | +0.05 (+0.65%) |
| Open | 7.75 |
| Prev. Close | 7.66 |
| Today's Range |
7.56
8.30
|
| 52wk Range |
2.34
11.55
|
| Volume | 68,700 |
| Avg Volume | 229,235 |
| Sector | SIC-2834 Pharmaceutical Preparations |
Perfomance Comparison
| Name | Today | 3-Month | 1-Year |
|---|---|---|---|
| ELYM |
 +0.65% |
 +176.34% |
+157.00% |
| DJIA |
+1.51% |
 -2.09% |
+16.90% |
| S&P 500 |
+0.80% |
+1.01% |
+25.49% |
Key Statistics
| Annual EPS | N/A |
|---|---|
| Dividend Yield | 0.00% |
| P/E Ratio | N/A |
| Market Capitalization, $K | 223,130 |
| Weighted Alpha | -11.74 |
| Standard Deviation | +0.09 |
| Profit Margin | N/A |
| Beta | -0.36 |
Growth Rates
| YTD | +185.56% | |||
| 1-Year | +161.36% |
Opinion
| Sell | Hold | Buy |
Recent Headlines
SHAREHOLDER ALERT: Kaskela Law LLC Announces
PR Newswire - Mon Apr 15, 07:15AM CDT
/PRNewswire/ -- Kaskela Law LLC, announces that it is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) ("Eliem") on behalf of the company's shareholders....(full story)
ELYM: 7.71 (+0.05)
Kuehn Law Encourages ALPN, JBT, ELYM, and HRT
PR Newswire - Thu Apr 11, 03:27PM CDT
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...(full story)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC
PR Newswire - Thu Apr 11, 12:02PM CDT
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...(full story)
ELYM Stock Alert: Halper Sadeh LLC Is Investigating
Business Wire - Thu Apr 11, 07:30AM CDT
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Eliem Therapeutics, Inc. (NASDAQ: ELYM) and Tenet Medicines, Inc. is fair to Eliem shareholders.(full story)
ELYM: 7.71 (+0.05)
Eliem Therapeutics Announces Agreement to Acquire
GlobeNewswire - Thu Apr 11, 06:00AM CDT
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have...(full story)
ELYM: 7.71 (+0.05)